Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 221

1.

A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis.

Stein MS, Liu Y, Gray OM, Baker JE, Kolbe SC, Ditchfield MR, Egan GF, Mitchell PJ, Harrison LC, Butzkueven H, Kilpatrick TJ.

Neurology. 2011 Oct 25;77(17):1611-8. doi: 10.1212/WNL.0b013e3182343274.

PMID:
22025459
2.

Management of worsening multiple sclerosis with mitoxantrone: a review.

Fox EJ.

Clin Ther. 2006 Apr;28(4):461-74. Review.

PMID:
16750460
3.

Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.

Hurwitz BJ, Jeffery D, Arnason B, Bigley K, Coyle P, Goodin D, Kaba S, Kirzinger S, Lynch S, Mandler R, Mikol D, Rammohan K, Sater R, Sriram S, Thrower B, Boateng F, Jakobs P, Wash MB, Bogumil T.

Clin Ther. 2008 Jun;30(6):1102-12. doi: 10.1016/j.clinthera.2008.06.013.

PMID:
18640466
5.

Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.

Togha M, Karvigh SA, Nabavi M, Moghadam NB, Harirchian MH, Sahraian MA, Enzevaei A, Nourian A, Ghanaati H, Firouznia K, Jannati A, Shekiba M.

Mult Scler. 2010 Jul;16(7):848-54. doi: 10.1177/1352458510369147. Epub 2010 May 20.

PMID:
20488825
6.

Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS.

Zivadinov R, Rudick RA, De Masi R, Nasuelli D, Ukmar M, Pozzi-Mucelli RS, Grop A, Cazzato G, Zorzon M.

Neurology. 2001 Oct 9;57(7):1239-47.

PMID:
11591843
7.

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P; FREEDOMS Study Group.

N Engl J Med. 2010 Feb 4;362(5):387-401. doi: 10.1056/NEJMoa0909494. Epub 2010 Jan 20.

8.

A reassessment of the plateauing relationship between T2 lesion load and disability in MS.

Sormani MP, Rovaris M, Comi G, Filippi M.

Neurology. 2009 Nov 10;73(19):1538-42. doi: 10.1212/WNL.0b013e3181c06679. Epub 2009 Sep 30.

PMID:
19794123
9.

Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS.

Cohen JA, Rovaris M, Goodman AD, Ladkani D, Wynn D, Filippi M; 9006 Study Group.

Neurology. 2007 Mar 20;68(12):939-44.

PMID:
17372130
10.

Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.

Kappos L, Traboulsee A, Constantinescu C, Erälinna JP, Forrestal F, Jongen P, Pollard J, Sandberg-Wollheim M, Sindic C, Stubinski B, Uitdehaag B, Li D.

Neurology. 2006 Sep 26;67(6):944-53.

PMID:
17000959
11.

Glatiramer acetate in combination with minocycline in patients with relapsing--remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial.

Metz LM, Li D, Traboulsee A, Myles ML, Duquette P, Godin J, Constantin M, Yong VW; GA/minocycline study investigators.

Mult Scler. 2009 Oct;15(10):1183-94. doi: 10.1177/1352458509106779. Epub 2009 Sep 23.

PMID:
19776092
12.

A randomized, double-blind, placebo-controlled MRI study of anti-herpes virus therapy in MS.

Bech E, Lycke J, Gadeberg P, Hansen HJ, Malmeström C, Andersen O, Christensen T, Ekholm S, Haahr S, Höllsberg P, Bergström T, Svennerholm B, Jakobsen J.

Neurology. 2002 Jan 8;58(1):31-6.

PMID:
11781402
13.

Short-term correlations between clinical and MR imaging findings in relapsing-remitting multiple sclerosis.

Rovaris M, Comi G, Ladkani D, Wolinsky JS, Filippi M; European/Canadian Glatiramer Acetate Study Group.

AJNR Am J Neuroradiol. 2003 Jan;24(1):75-81.

14.

Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.

Río J, Rovira A, Tintoré M, Huerga E, Nos C, Tellez N, Tur C, Comabella M, Montalban X.

Mult Scler. 2008 May;14(4):479-84. doi: 10.1177/1352458507085555.

PMID:
18562504
15.

Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study.

Saida T, Tashiro K, Itoyama Y, Sato T, Ohashi Y, Zhao Z; Interferon Beta-1b Multiple Sclerosis Study Group of Japan.

Neurology. 2005 Feb 22;64(4):621-30.

PMID:
15728282
16.

Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?

Barkhof F, Hulst HE, Drulovic J, Uitdehaag BM, Matsuda K, Landin R; MN166-001 Investigators.

Neurology. 2010 Mar 30;74(13):1033-40. doi: 10.1212/WNL.0b013e3181d7d651. Epub 2010 Mar 3.

PMID:
20200338
17.

Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon β-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial.

Smolders J, Hupperts R, Barkhof F, Grimaldi LM, Holmoy T, Killestein J, Rieckmann P, Schluep M, Vieth R, Hostalek U, Ghazi-Visser L, Beelke M; SOLAR study group.

J Neurol Sci. 2011 Dec 15;311(1-2):44-9. doi: 10.1016/j.jns.2011.04.013. Epub 2011 May 28.

PMID:
21620416
18.

Bimonthly assessment of magnetization transfer magnetic resonance imaging parameters in multiple sclerosis: a 14-month, multicentre, follow-up study.

Mesaros S, Rocca M, Sormani M, Valsasina P, Markowitz C, De Stefano N, Montalban X, Barkhof F, Ranjeva J, Sailer M, Kappos L, Comi G, Filippi M.

Mult Scler. 2010 Mar;16(3):325-31. doi: 10.1177/1352458509358713. Epub 2010 Jan 19.

PMID:
20086023
19.

Ingested IFN-alpha: results of a pilot study in relapsing-remitting MS.

Brod SA, Lindsey JW, Vriesendorp FS, Ahn C, Henninger E, Narayana PA, Wolinsky JS.

Neurology. 2001 Sep 11;57(5):845-52.

PMID:
11552015
20.

Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects.

O'Connor PW, Goodman A, Willmer-Hulme AJ, Libonati MA, Metz L, Murray RS, Sheremata WA, Vollmer TL, Stone LA; Natalizumab Multiple Sclerosis Trial Group.

Neurology. 2004 Jun 8;62(11):2038-43.

PMID:
15184611

Supplemental Content

Support Center